Latest Ratios: P/E Ratio 31.4x · EV/EBITDA 9.1x · ROE 10.8%. (2014–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $446M | $303M | $327M | $317M | $301M | $212M | $314M | $246M | $151M | — | — |
| Enterprise Value | $448M | $306M | $317M | $314M | $285M | $190M | $295M | $253M | $144M | — | — |
| P/E Ratio → | 31.43 | 20.08 | 28.64 | 31.40 | 50.40 | 23.73 | 9.46 | 28.18 | 14.62 | — | — |
| P/S Ratio | 1.65 | 1.12 | 1.46 | 1.73 | 2.17 | 1.81 | 2.39 | 3.07 | 2.31 | — | — |
| P/B Ratio | 3.31 | 2.11 | 2.46 | 2.78 | 3.10 | 2.24 | 3.85 | 5.64 | 4.30 | — | — |
| P/FCF | 37.37 | 25.42 | 248.30 | 16.58 | 62.05 | 77.19 | 14.25 | 43.22 | 9.28 | — | — |
| P/OCF | 8.59 | 5.84 | 8.37 | 7.01 | 10.85 | 9.44 | 8.96 | 12.91 | 6.74 | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.13 | 1.41 | 1.72 | 2.05 | 1.63 | 2.24 | 3.15 | 2.20 | — | — |
| EV / EBITDA | 9.09 | 6.20 | 7.32 | 8.69 | 11.92 | 8.32 | 8.10 | 16.56 | 6.90 | — | — |
| EV / EBIT | 21.65 | 13.32 | 18.68 | 21.23 | 30.99 | 14.86 | 10.96 | 27.73 | 14.22 | — | — |
| EV / FCF | — | 25.63 | 240.20 | 16.45 | 58.71 | 69.23 | 13.35 | 44.30 | 8.85 | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 57.5% | 57.5% | 59.4% | 61.6% | 61.0% | 62.7% | 61.0% | 69.8% | 74.4% | 73.8% | 60.1% |
| Operating Margin | 7.7% | 7.7% | 8.0% | 7.8% | 5.9% | 9.9% | 20.4% | 11.0% | 26.1% | 18.8% | 1.2% |
| Net Profit Margin | 5.5% | 5.5% | 5.0% | 5.6% | 4.5% | 7.8% | 24.0% | 10.6% | 15.6% | 17.4% | 3.9% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 10.8% | 10.8% | 9.1% | 9.7% | 6.5% | 10.3% | 50.3% | 21.7% | 34.6% | 44.6% | 10.0% |
| ROA | 7.6% | 7.6% | 6.8% | 7.5% | 5.3% | 7.9% | 32.3% | 12.5% | 22.3% | 26.2% | 5.2% |
| ROIC | 11.6% | 11.6% | 11.5% | 11.2% | 8.0% | 12.9% | 36.0% | 17.1% | 49.3% | 34.1% | 1.9% |
| ROCE | 13.2% | 13.2% | 13.6% | 13.0% | 8.3% | 12.2% | 36.6% | 19.0% | 55.8% | 44.1% | 2.6% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.11 | 0.11 | 0.05 | 0.09 | 0.01 | 0.07 | 0.14 | 0.45 | 0.10 | 0.22 | 0.50 |
| Debt / EBITDA | 0.32 | 0.32 | 0.16 | 0.29 | 0.03 | 0.28 | 0.31 | 1.28 | 0.16 | 0.46 | 3.59 |
| Net Debt / Equity | — | 0.02 | -0.08 | -0.02 | -0.17 | -0.23 | -0.24 | 0.14 | -0.20 | 0.00 | 0.17 |
| Net Debt / EBITDA | 0.05 | 0.05 | -0.25 | -0.07 | -0.68 | -0.96 | -0.55 | 0.40 | -0.34 | 0.01 | 1.19 |
| Debt / FCF | — | 0.21 | -8.10 | -0.13 | -3.34 | -7.96 | -0.90 | 1.08 | -0.43 | 0.01 | 0.45 |
| Interest Coverage | 19.42 | 19.42 | 21.84 | 34.94 | 46.63 | 40.32 | 52.79 | 29.01 | 55.86 | 32.44 | 1.19 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.18 | 1.18 | 1.42 | 1.19 | 2.11 | 2.66 | 2.05 | 1.07 | 1.35 | 1.29 | 1.22 |
| Quick Ratio | 1.06 | 1.06 | 1.30 | 1.05 | 1.92 | 2.52 | 1.95 | 1.02 | 1.18 | 1.17 | 1.04 |
| Cash Ratio | 0.33 | 0.33 | 0.47 | 0.40 | 0.90 | 1.59 | 1.35 | 0.52 | 0.61 | 0.39 | 0.47 |
| Asset Turnover | — | 1.26 | 1.27 | 1.18 | 1.19 | 0.99 | 1.17 | 0.97 | 1.22 | 1.25 | 1.27 |
| Inventory Turnover | 22.75 | 22.75 | 21.08 | 15.17 | 15.15 | 17.77 | 22.16 | 17.83 | 5.78 | 7.54 | 7.63 |
| Days Sales Outstanding | — | 34.55 | 40.55 | 36.80 | 40.50 | 45.88 | 34.39 | 52.46 | 49.43 | 76.08 | 55.79 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 3.2% | 5.0% | 3.5% | 3.2% | 2.0% | 4.2% | 10.6% | 3.5% | 6.8% | — | — |
| FCF Yield | 2.7% | 3.9% | 0.4% | 6.0% | 1.6% | 1.3% | 7.0% | 2.3% | 10.8% | — | — |
| Buyback Yield | 3.0% | 4.4% | 0.3% | 0.2% | 3.2% | 0.7% | 0.0% | 0.6% | 1.1% | — | — |
| Total Shareholder Yield | 3.0% | 4.4% | 0.3% | 0.2% | 3.2% | 0.7% | 0.0% | 0.6% | 1.1% | — | — |
| Shares Outstanding | — | $41M | $41M | $40M | $40M | $41M | $41M | $40M | $40M | $38M | $38M |
Regulatory reimbursement and audit exposure
Based on current market data, VMD trades at a forward P/E of 25.56, suggesting that investors are pricing in significant future earnings expansion despite the inherent volatility in the company's quarterly net income and the ongoing regulatory risks associated with the U.S. respiratory healthcare reimbursement environment.
The current P/E multiple appears to command a premium relative to the company's historical earnings volatility, implying that the market is valuing VMD as a high-growth service provider rather than a traditional equipment renter. Investors should monitor whether this valuation can be sustained if the company's operating margins continue to face pressure from rising clinical labor costs.
As reported in financial statements, VMD's ROIC has struggled to gain sustained momentum, fluctuating between 1.4% and 4.4% over the last ten quarters, which indicates that the company's aggressive reinvestment in its equipment fleet has yet to yield a consistent, high-return compounding effect on invested capital.
The low ROIC figures suggest that the capital-intensive nature of the respiratory equipment business acts as a drag on overall returns. While the company is successfully expanding its footprint, the current returns on capital appear insufficient to justify a high-growth valuation without significant improvements in operating leverage.
According to recent quarterly filings, VMD's cash conversion cycle has shown significant variability, ranging from 11 to 36 days, which reflects the inherent challenges in managing complex healthcare billing cycles and the potential for delayed cash collections from private and government payers in the respiratory space.
The fluctuation in the CCC suggests that VMD's working capital efficiency is highly sensitive to the timing of reimbursements. Investors should scrutinize whether the recent trend toward longer collection periods indicates a structural shift in payer behavior or merely temporary administrative bottlenecks in the billing process.
The P/E ratio is frequently misapplied to VMD because it fails to account for the heavy non-cash depreciation charges inherent in the company's rental-heavy business model, which significantly obscures the firm's true underlying cash-generating capacity and its ability to fund future growth through internal operations.
Analysts should prioritize EV/EBITDA or P/FCF over P/E to better capture the economic reality of the business, as these metrics normalize for the high depreciation of medical equipment. Relying solely on P/E may lead to an inaccurate assessment of the company's valuation relative to its actual cash-flow-generating potential.
Includes 30+ ratios · 12 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying VMD stock.
Viemed Healthcare, Inc.'s current P/E ratio is 31.4x. The historical average is 25.8x. This places it at the 88th percentile of its historical range.
Viemed Healthcare, Inc.'s current EV/EBITDA is 9.1x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 9.3x.
Viemed Healthcare, Inc.'s return on equity (ROE) is 10.8%. The historical average is 34.1%.
Based on historical data, Viemed Healthcare, Inc. is trading at a P/E of 31.4x. This is at the 88th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Viemed Healthcare, Inc. has 57.5% gross margin and 7.7% operating margin.
Viemed Healthcare, Inc.'s Debt/EBITDA ratio is 0.3x, indicating low leverage. A ratio below 2x is generally considered financially healthy.